Cognetivity Neurosciences Ltd. Logo

Cognetivity Neurosciences Ltd.

CGN.CN

(1.8)
Stock Price

0,01 CAD

-2466.82% ROA

69.23% ROE

-0.1x PER

Market Cap.

895.886,00 CAD

-38.72% DER

0% Yield

-8732.77% NPM

Cognetivity Neurosciences Ltd. Stock Analysis

Cognetivity Neurosciences Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cognetivity Neurosciences Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (138.8%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-0.78x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-10%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

6 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

7 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

8 ROA

The stock's ROA (-2423.52%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

9 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

11 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Cognetivity Neurosciences Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cognetivity Neurosciences Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Cognetivity Neurosciences Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cognetivity Neurosciences Ltd. Revenue
Year Revenue Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 45.366 100%
2023 116.624 61.1%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cognetivity Neurosciences Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2015 0
2016 63.092 100%
2017 82.141 23.19%
2018 732.366 88.78%
2019 492.181 -48.8%
2020 70.996 -593.25%
2021 491.228 85.55%
2022 601.149 18.29%
2023 172.356 -248.78%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cognetivity Neurosciences Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 51.489
2016 385.688 86.65%
2017 1.402.010 72.49%
2018 2.620.064 46.49%
2019 1.702.088 -53.93%
2020 2.144.449 20.63%
2021 3.753.526 42.87%
2022 5.038.903 25.51%
2023 3.385.876 -48.82%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cognetivity Neurosciences Ltd. EBITDA
Year EBITDA Growth
2015 13.471
2016 -494.364 102.72%
2017 -1.485.430 66.72%
2018 -4.206.649 64.69%
2019 -2.595.509 -62.07%
2020 -1.866.140 -39.08%
2021 -13.032.930 85.68%
2022 -6.271.761 -107.8%
2023 -3.544.264 -76.96%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cognetivity Neurosciences Ltd. Gross Profit
Year Gross Profit Growth
2015 -10.972
2016 -240 -4471.67%
2017 -1.434 83.26%
2018 -3.942 63.62%
2019 -9.292 57.58%
2020 -11.448 18.83%
2021 -24.530 53.33%
2022 -2.129.868 98.85%
2023 88.668 2502.07%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cognetivity Neurosciences Ltd. Net Profit
Year Net Profit Growth
2015 -68.648
2016 -458.844 85.04%
2017 -1.495.804 69.32%
2018 -4.192.618 64.32%
2019 -2.645.114 -58.5%
2020 -1.928.097 -37.19%
2021 -13.127.327 85.31%
2022 -7.433.815 -76.59%
2023 -8.146.424 8.75%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cognetivity Neurosciences Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cognetivity Neurosciences Ltd. Free Cashflow
Year Free Cashflow Growth
2015 188
2016 -329.447 100.06%
2017 -868.313 62.06%
2018 -3.511.805 75.27%
2019 -1.878.426 -86.95%
2020 -2.008.822 6.49%
2021 -3.314.545 39.39%
2022 -6.012.037 44.87%
2023 -1.685 -356697.45%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cognetivity Neurosciences Ltd. Operating Cashflow
Year Operating Cashflow Growth
2015 188
2016 -326.183 100.06%
2017 -859.730 62.06%
2018 -3.490.696 75.37%
2019 -1.856.603 -88.02%
2020 -1.958.741 5.21%
2021 -3.214.534 39.07%
2022 -5.942.352 45.9%
2023 16.935 35189.18%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cognetivity Neurosciences Ltd. Capital Expenditure
Year Capital Expenditure Growth
2015 0
2016 3.264 100%
2017 8.583 61.97%
2018 21.109 59.34%
2019 21.823 3.27%
2020 50.081 56.42%
2021 100.011 49.92%
2022 69.685 -43.52%
2023 18.620 -274.25%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cognetivity Neurosciences Ltd. Equity
Year Equity Growth
2015 -122.522
2016 -99.430 -23.22%
2017 3.388.357 102.93%
2018 479.410 -606.78%
2019 -263.035 282.26%
2020 862.911 130.48%
2021 -5.675.378 115.2%
2022 -9.889.538 42.61%
2023 -15.195.374 34.92%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cognetivity Neurosciences Ltd. Assets
Year Assets Growth
2015 547
2016 68.473 99.2%
2017 3.754.403 98.18%
2018 716.321 -424.12%
2019 748.065 4.24%
2020 1.827.799 59.07%
2021 2.004.830 8.83%
2022 2.829.418 29.14%
2023 486.605 -481.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cognetivity Neurosciences Ltd. Liabilities
Year Liabilities Growth
2015 123.068
2016 167.903 26.7%
2017 366.046 54.13%
2018 236.911 -54.51%
2019 1.011.100 76.57%
2020 964.888 -4.79%
2021 7.680.208 87.44%
2022 12.718.956 39.62%
2023 15.681.979 18.89%

Cognetivity Neurosciences Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.1
Price to Earning Ratio
-0.1x
Price To Sales Ratio
9.05x
POCF Ratio
-0.23
PFCF Ratio
-0.23
Price to Book Ratio
-0.06
EV to Sales
22.71
EV Over EBITDA
-0.53
EV to Operating CashFlow
-0.58
EV to FreeCashFlow
-0.58
Earnings Yield
-9.78
FreeCashFlow Yield
-4.33
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.62
Graham NetNet
-0.18

Income Statement Metrics

Net Income per Share
-0.1
Income Quality
0.45
ROE
0.69
Return On Assets
-17.76
Return On Capital Employed
0.31
Net Income per EBT
1
EBT Per Ebit
2.01
Ebit per Revenue
-43.34
Effective Tax Rate
-0.53

Margins

Sales, General, & Administrative to Revenue
39.22
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
5.99
Gross Profit Margin
-5.36
Operating Profit Margin
-43.34
Pretax Profit Margin
-87.33
Net Profit Margin
-87.33

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.04
Free CashFlow per Share
-0.04
Capex to Operating CashFlow
0.01
Capex to Revenue
-0.29
Capex to Depreciation
-1.09
Return on Invested Capital
0.7
Return on Tangible Assets
-24.67
Days Sales Outstanding
928.56
Days Payables Outstanding
670.71
Days of Inventory on Hand
0
Receivables Turnover
0.39
Payables Turnover
0.54
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,17
Tangible Book Value per Share
-0.17
Shareholders Equity per Share
-0.17
Interest Debt per Share
0.12
Debt to Equity
-0.39
Debt to Assets
12.09
Net Debt to EBITDA
-0.32
Current Ratio
0.02
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-0.39
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0.28
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
6.57

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cognetivity Neurosciences Ltd. Dividends
Year Dividends Growth

Cognetivity Neurosciences Ltd. Profile

About Cognetivity Neurosciences Ltd.

Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that helps to detect the earliest signs of impairment by testing the performance of large areas of the brain to support the diagnosis of dementia; and offers OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.

CEO
Dr. Sina Habibi
Employee
2.500
Address
1055 West Hastings Street
Vancouver, V6E 2E9

Cognetivity Neurosciences Ltd. Executives & BODs

Cognetivity Neurosciences Ltd. Executives & BODs
# Name Age
1 Mr. Desmond M. Balakrishnan B.A., L.L.B.
Legal Counsel & Director
70
2 Dr. Thomas Roger Sawyer M.B.A., Ph.D.
Chief Financial Officer, Company Secretary & Director
70
3 Dr. Sina Habibi
Co-Founder, Chief Executive Officer & Director
70
4 Dr. Seyed-Mahdi Khaligh-Razavi
Co-Founder & Chief Information Officer
70

Cognetivity Neurosciences Ltd. Competitors